Unleashing Funding: Accelerating Clinical Trials with Digital Twin Technology

Unlearn, an AI company, has secured $50 million in a Series C funding round led by Altimeter Capital to advance its mission of reducing trial and error in medicine through the use of AI. Unlearn aims to tackle challenges associated with clinical research, such as extended timelines, sluggish enrollment, and reluctance of patients due to the possibility of receiving a placebo. Since its inception in 2017, Unlearn has secured more than $130 million for developing AI solutions that create digital twins for trial participants, leading to smaller, quicker studies. The company’s AI models create a digital twin for each participant before they are randomized into the trial’s experimental or control arm, enabling highly powered trials that have smaller control groups. Unlearn has collaborated with regulatory experts and received qualification from the European Medicines Agency for use in Phase II and III clinical trials with continuous outcomes.